Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma
Authors:
- Kenya KamimuraKKKenya Kamimura
- Takeshi YokooTYTakeshi Yokoo
- Hiroyuki AbeHAHiroyuki Abe
- Norihiro SakaiNSNorihiro Sakai
- Takuro NagoyaTNTakuro Nagoya
- Yuji KobayashiYKYuji Kobayashi
- Masato OhtsukaMOMasato Ohtsuka
- Hiromi MiuraHMHiromi Miura
- Akira SakamakiASAkira Sakamaki
- Hiroteru KamimuraHKHiroteru Kamimura
- Norio MiyamuraNMNorio Miyamura
- Hiroshi NishinaHiroshi Nishina
Open Access
Abstract
Hepatocellular carcinoma (HCC) is a major global malignancy, responsible for >90% of primary liver cancers. Currently available therapeutic options have poor performances due to the highly heterogeneous nature of the tumor cells; recurrence is highly probable, and some patients develop resistances to the therapies. Accordingly, the development of a novel therapy is essential. We assessed gene therapy for HCC using a diphtheria toxin fragment A (DTA) gene-expressing plasmid, utilizing a non-viral hydrodynamics-based procedure. The antitumor effect of DTA expression in HCC cell lines (and alpha-fetoprotein (AFP) promoter selectivity) is assessed in vitro by examining HCC cell growth. Moreover, the effect and safety of the AFP promoter-selective DTA expression was examined in vivo using an HCC mice model established by the hydrodynamic gene delivery of the yes-associated protein (YAP)-expressing plasmid. The protein synthesis in DTA transfected cells is inhibited by the disappearance of tdTomato and GFP expression co-transfected upon the delivery of the DTA plasmid; the HCC cell growth is inhibited by the expression of DTA in HCC cells in an AFP promoter-selective manner. A significant inhibition of HCC occurrence and the suppression of the tumor marker of AFP and des-gamma-carboxy prothrombin can be seen in mice groups treated with hydrodynamic gene delivery of DTA, both 0 and 2 months after the YAP gene delivery. These results suggest that DTA gene therapy is effective for HCC.Keywords
Funding Information
- Japan Society for the Promotion of Science (22890064, 23790595, 26860354, and 17K09408)
- Takara Bio Award from JSGT (2013)
- Japan Agency for Medical Research and Development (JP19fk0210042)
This publication has 68 references indexed in Scilit:
- Diphtheria toxin/human B-Cell activating factor fusion protein kills human acute lymphoblastic leukemia BALL-1 cells: An experimental studyChinese Journal of Cancer Research, 2012
- Exploiting the Intron-splicing Mechanism of Insect Cells to Produce Viral Vectors Harboring Toxic Genes for Suicide Gene TherapyMolecular Therapy Nucleic Acids, 2012
- Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic CancerJournal of Oncology, 2010
- A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinomaCancer Gene Therapy, 2010
- Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequencesJournal of Translational Medicine, 2009
- Image-guided, Lobe-specific Hydrodynamic Gene Delivery to Swine LiverMolecular Therapy, 2009
- Physical Approaches for Nucleic Acid Delivery to LiverThe AAPS Journal, 2008
- Optimization of a synthetic β-catenin-dependent promoter for tumor-specific cancer gene therapyMolecular Therapy, 2004
- Selective Inhibition of Hepatoma Cells Using Diphtheria Toxin A under the Control of the Promoter/Enhancer Region of the Human α‐Fetoprotein GeneJapanese Journal of Cancer Research, 2000
- Biology and Molecular Epidemiology of Diphtheria Toxin and thetoxGeneThe Journal of Infectious Diseases, 2000